此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估 GEN1057 在恶性实体瘤中的安全性和抗肿瘤活性的试验

2026年11月2日 更新者:Genmab

一项首次人体、开放标签、剂量递增试验,旨在评估 GEN1057 在恶性实体瘤受试者中的安全性和抗肿瘤活性

The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer.

Trial details include:

  • The trial duration for an individual participant will be up to approximately 11 months.
  • The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months.

Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.

研究概览

详细说明

The trial is a first-in-human (FIH) open-label, multicenter, multinational safety trial.

The dose escalation will evaluate different dose levels by assessing safety, tolerability, and early efficacy signals to determine the expansion dose(s) of GEN1057 as monotherapy, as well as characterizing the pharmacokinetic (PK) profile and immunogenicity in participants with malignant solid tumors who have metastatic or advanced disease.

研究类型

介入性

注册 (实际的)

23

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Tokyo、日本
        • National Cancer Center, Tsukiji 5-1-1
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • SCRI Oncology Partners
    • Texas
      • San Antonio、Texas、美国、78229
        • South Texas Accelerated Research Therapeutics, LLC
      • Madrid、西班牙、28050
        • Start Madrid Centro Integral Oncologico Clara Campal CIOCC
    • Barcelona
      • Barcelona、Barcelona、西班牙、08035
        • Hospital Universitari Vall d'Hebron

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Advanced and/or metastatic malignant solid tumors, who have progressed on standard of care therapy for whom there is no available standard therapy likely to provide clinical benefit, or who are not candidates for available therapy, and for whom experimental therapy with GEN1057 may be beneficial, in the opinion of the investigator.
  • Be at least 18 (or the legal age of consent in the jurisdiction in which the trial is taking place) years of age.
  • Have measurable disease according to RECIST v1.1.
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 at screening and on C1D1 pretreatment. Note: If screening ECOG PS is assessed within 3 days prior to C1D1, ECOG PS does not need to be reassessed at C1D1.
  • Have a life expectancy of ≥3 months.

Key Exclusion Criteria:

  • Has been exposed to any of the following prior therapies/treatments within the specified timeframes:

    • Treatment with an investigational anticancer agent within 28 days or for systemic therapies within 5 half-lives of the drug, whichever is shorter, prior to trial treatment administration.
    • Treatment with an investigational drug, including investigational vaccines within 28 days before the planned first dose of trial treatment.
    • Prior treatment with live, attenuated vaccines within 28 days prior to initiation of GEN1057. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live, attenuated vaccines and are not allowed. Experimental and/or nonauthorized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations are not allowed.
    • Used an invasive investigational medical device within 28 days before the planned first dose of trial treatment.
  • Has clinically significant toxicities from previous anticancer therapies that have not resolved to baseline levels or to grade 1, except for anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to ≤ grade 2. There is no limitation for alopecia and hearing impairment from previous therapies.

  • Has known, symptomatic brain metastases. Asymptomatic brain metastases are allowed provided that they have been treated, have been stable for >28 days as documented by radiographic imaging, and do not require prolonged (>14 days) systemic corticosteroid therapy.

  • Has a past or current malignancy other than inclusion diagnosis.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:GEN1057单一疗法

Intravenous (IV) infusion

IV infusion/orally by mouth.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
出现治疗中出现的不良事件 (AE) 的参与者人数
大体时间:从第一次给药到安全随访期结束(约5个月)
从第一次给药到安全随访期结束(约5个月)
Number of Participants With Dose Limiting Toxicities (DLTs)
大体时间:Up to 21 days

DLTs will be graded for severity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v5.0.

Up to 21 days

次要结果测量

结果测量
措施说明
大体时间
GEN1057 的最大血浆浓度 (Cmax)
大体时间:给药前和给药后多个时间点直至治疗结束(约 4 个月)
给药前和给药后多个时间点直至治疗结束(约 4 个月)
GEN1057 达到 Cmax (Tmax) 的时间
大体时间:给药前和给药后多个时间点直至治疗结束(约 4 个月)
给药前和给药后多个时间点直至治疗结束(约 4 个月)
GEN1057 从零时间到最后一个可定量样品 (AUC0-last) 的浓度-时间曲线下面积 (AUC)
大体时间:给药前和给药后多个时间点直至治疗结束(约 4 个月)
给药前和给药后多个时间点直至治疗结束(约 4 个月)
GEN1057 的半衰期 (t1/2)
大体时间:给药前和给药后多个时间点直至治疗结束(约 4 个月)
给药前和给药后多个时间点直至治疗结束(约 4 个月)
GEN1057 血浆清除率 (CL)
大体时间:给药前和给药后多个时间点直至治疗结束(约 4 个月)
给药前和给药后多个时间点直至治疗结束(约 4 个月)
Number of Participants with Anti-drug Antibodies (ADAs) to GEN1057
大体时间:Up to approximately 11 months

Serum samples will be screened for ADAs binding to GEN1057 and the titer of confirmed positive samples will be reported.

Up to approximately 11 months
Objective Response Rate (ORR)
大体时间:Up to approximately 11 months

The ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST) version (v) 1.1 as assessed by the investigator.

Up to approximately 11 months
Duration of Response (DOR)
大体时间:Up to approximately 11 months

DOR is defined as the time from the first documentation of response (CR or PR) to the date of progressive disease (PD) or death, whichever occurs earlier based on RECIST v1.1 as assessed by the investigator.

Up to approximately 11 months
Time to Response (TTR)
大体时间:Up to approximately 11 months

TTR is defined as the time from Cycle 1 Day 1 (C1D1) to the first documentation of objective response (CR or PR) in participants achieving PR or CR based on RECIST v1.1 as assessed by the investigator.

Up to approximately 11 months
Disease Control Rate (DCR)
大体时间:Up to approximately 11 months

DCR is defined as the percentage of participants with BOR of CR, PR, or stable disease (SD) based on RECIST v1.1 as assessed by the investigator.

Up to approximately 11 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Study Official、Genmab

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年8月28日

初级完成 (实际的)

2026年4月7日

研究完成 (实际的)

2026年4月7日

研究注册日期

首次提交

2024年8月26日

首先提交符合 QC 标准的

2024年8月26日

首次发布 (实际的)

2024年8月27日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • GCT1057-01
  • 2024-513563-75-00 (克蒂斯)
  • jRCT2031240508 (注册表标识符:Japan Registry of Clinical Trials)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅